IVA - Inventiva S.A.
3.1
0.035 1.129%
Share volume: 67,395
Last Updated: 04-07-2025
Pharmaceutical Products/Pharmaceutical Preparations:
0.00%
PREVIOUS CLOSE
CHG
CHG%
$3.06
0.04
0.01%
Fundamental analysis
8%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
20%
Performance
5 Days
-1.13%
1 Month
-1.45%
3 Months
-3.02%
6 Months
-3.02%
1 Year
-3.02%
2 Year
-3.02%
Key data
Stock price
$3.10
DAY RANGE
$2.90 - $3.25
52 WEEK RANGE
$2.67 - $3.46
52 WEEK CHANGE
-$3.02
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
09-24-2025
Company detail
CEO: Frédéric Cren
Region: US
Website: inventivapharma.com
Employees: 100
IPO year: 2020
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: inventivapharma.com
Employees: 100
IPO year: 2020
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Inventiva S.A. focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH.
Recent news
